Table 3 Comparison of treatment outcomes of MDR/XDR-TB cases according to daily administered linezolid dose
Outcome | ≤600 mg linezolid n (%) | >600 mg linezolid n (%) | Difference (%) (95 % CI) | p value |
|---|---|---|---|---|
Culture conversion | 184/215 (85.58) | 39/41 (95.12) | 9.54 (−2.29–16.32 %) | p = 0.0948 |
Treatment success | 134/176 (76.14) | 34/38 (89.47) | 13.34 (−13.22–23.12 %) | p = 0.0695 |
Myelosuppression | 47/240 (19.58) | 24/48 (50.00) | 30.42 (15.77–44.94 %) | p < 0.0001 |
Neuropathy | 82/240 (34.17) | 20/48 (41.67) | 7.5 % (−6.84–22.79 %) | p = 0.3213 |
Linezolid discontinuation | 40/222 (18.02) | 9/48 (18.75) | 0.73 % (−9.66–14.72 %) | p = 0.9050 |